You forgot one bearechimp
freddyaophelps • Jun 10, 2014 12:16 PM
godfrey, ACTC could easily double or triple (maybe more) when trial results are published later this year, why buy a lesser product like STEM when you can buy the best at a discount? All the developmental stage stem cell companies have the same dilution and funding issues. If I was 79 years old I would sell some when trial results are released and take the proceeds to fund a vacation to an Arizona cat house for a couple weeks. You're only 79 once : )
History will repeat
Trade libel is defined as the publication of a false statement of fact that is an intentional disparagement of the quality of the services or products of the plaintiff's business and that result in pecuniary damages to the plaintiff.
Some of the "bearefaced" lies currently being posted may fall under this category.
Re: Full time?
bearechimp did you know you are entitled to full time and a half over 40 hours and at least double time on holidays?
The FLSA requires that most employees in the United States be paid at least the federal minimum wage for all hour worked and overtime pay at time and one-half the regular rate of pay for all hours worked over 40 in a workweek.
Paid holidays and overtime end when bashchimping begins.
Hello bearechimp! You buying today to? The only way I can thank you for your hard work is with a reply, don't spend it all in one place.
keep_investing • Nov 20, 2014 4:12 PM
Freddy, one reason we bashers work so hard...
kittykat got your tongue keepee?
Bearechimp am I the first person you think of EVERY morning? Does the big scary Proprietary HMC™ cell line interfere with your sleep?
It's all in the latest webcast, waiting for FDA to give the protocol. It's the bashers job to create confusion.
Authors' reply 7/05/2015
Steven D Schwartz, Eddy Anglade, Robert Lanza on behalf of the Ocata Macular Disease Investigator Group
See above, interesting read.
Listen to the webcast if you don't trust the transcript. Knowledge is power.
Past Events - Cantor Fitzgerald Inaugural Healthcare Conference
July 8, 2015 • 11:15 am ET Le Parker Meridien Hotel, New York, NY
Tuesday, October 14, 2014
Published study shows: ACT treatment restores some sight
By Lisa Eckelbecker TELEGRAM & GAZETTE STAFF
"We treated the last UK patients last month, and they also have not seen any safety issues related to the transplanted tissues themselves, either," Dr. Lanza said.
Did you forget about posting this a few months ago kittypaw?
kittypaw here's a reply so you can collect a $1, don't know how else to thank you for your efforts and yes I'm buying.
Bet you are to.
MARLBOROUGH, Mass.-- Ocata Therapeutics, Inc. (“Ocata”; NASDAQ:OCAT), a leader in the field of regenerative ophthalmology, today announced that the company has completed dosing of its Phase 1/2 studies for dry age-related macular degeneration (AMD) and Stargardt’s Macular Degeneration (SMD). A total of 38 patients have been safely dosed. The 200,000 cell cohort, the highest level planned was successfully completed, paving the way for the next phase of the programs.
Bashchimps are such drama queens.
Institutions have loaded up on OCAT. Recommendations have begun. Bashers working hard... always a good buy signal.
Ocata, where the progression of blindness ends and vision restoration begins